Plasmagen Biosciences taps into the niche Indian Biopharmaceutical market with the launch of CSL’s Haemocomplettan® P
Haemocomplettan® P will cater to the 1,50,000 cardiac surgeries and over 1,800 liver transplant patients who are at risk of massive bleeding due to acquired...